Dr. Maccecchini founded Annovis in May 2008 to develop better therapeutics for Alzheimer’s, Parkinson’s and other neurodegenerative diseases. Was partner and director of two angel groups, Robin Hood Ventures and MidAtlantic Angel Group; Founder and CEO of Symphony Pharmaceuticals/Annovis a biotech company that sold in 2001 to Transgenomic; General Manager of Bachem Bioscience, the US subsidiary of Bachem AG, Switzerland and Head Molecular Biology Mallinckrodt; Dr. Maccecchini did one postdoc at Caltech and one at the Roche Institute of Immunology, her PhD in biochemistry is from the Biocenter of Basel with a two-year visiting fellowship at The Rockefeller University.

Dr. Fang is an accomplished neuroscientist with two decades of experience in neurodegenerative diseases with broad scientific knowledge and hands-on experience. She has a successful track record of scientific publications and contributions. Dr. Fang has deep drug development knowledge with both pre-clinical and clinical development experience.

Dr. Christie has spent over 40 years in the pharmaceutical industry, with a focus on process chemistry R&D, pilot plant production and GMP operations. He has held senior management positions in both large (SmithKline, Rhodia, Teva) and mid-size (Cephalon) companies, as well as being the founder of a company providing contract process R&D services (later acquired by ChiRex). Dr. Christie is co-author or co-inventor on several publications and patents. He earned his BS in chemistry from the University of Michigan and his doctorate from MIT.

Ms. Gaines is an accomplished clinical research professional with over 20 years’ experience garnered from positions held in academia, contract research organizations and pharmaceutical companies. She has proven abilities in monitoring and management of Phase I to Phase IV clinical trials, specializing in CNS disorders and extending to a broad range of therapeutic indications. Her CNS experience spans from small Phase I and II studies to large global Phase III trials in Alzheimer’s disease, Parkinson’s disease, sleep disorders, and many psychiatric diseases in both adult and pediatric populations. She has demonstrated proven success in leading cross-functional teams as well as driving operational success. In her current role as VP, Clinical Operations she oversees and supports all clinical project activities.

Ms. Damiano has spent over 35 years in the biotechnology sector, focusing on the definition and execution of regulatory strategies and GxP compliance, encompassing early phase development through commercialization. Ms. Damiano has held various senior management positions throughout her career, with experience garnered at companies including Centocor, MedImmune, OraSure Technologies and Vicuron Pharmaceuticals. Ms. Damiano holds an accomplished track record in the definition and execution of regulatory strategies, including the development of innovative solutions and effective management of projects and resources to meet company objectives.

Mark White is a seasoned biopharmaceutical leader with over two decades of global and U.S. experience in pharmaceutical and biotech marketing, business development, and strategic leadership. His extensive expertise spans various therapeutic areas, including rheumatology, dermatology, pain, neuroscience, cardiovascular, and rare diseases. Mark has held significant leadership roles at prominent pharmaceutical companies such as Pfizer, Bracco, Abbott, and Bayer. At Annovis, Mark is leading business development and fund raising while driving the commercialization of buntanetap.

Sarah MacCallum is an experienced Clinical Project Manager and Registered Nurse, who has spent over a decade building skills in clinical research on a foundation of direct patient care. Her clinical trial background includes neuro-oncology, breast and bowel cancer, cardiology, pediatric organ transplant, and neuromuscular disorders. She has worked at the site, CRO, and sponsor levels in various roles before joining the Annovis Bio team as Senior Clinical Project Manager for Clinical Operations. Sarah received her Bachelor of Science in Nursing from Saint Louis University and a Bachelor of Arts in English from The Ohio State University.

Mr. Walsh has over 12 years of diverse finance experience at public and private companies. Prior to joining Annovis, Mr. Walsh served as Senior Director, Finance and Treasury at Ocugen, a Nasdaq-listed biotech developing gene and cell therapies. There he provided oversight over all areas of finance, including SEC Reporting, FP&A, as well as Treasury. Andrew also previously served as Director, Treasury and Tax at Potters Industries, a private equity sponsored materials manufacturer. At Potters, he was instrumental in the implementation of a $650M buy-side structure owned by The Jordan Company. Prior to that, Mr. Walsh worked for Potters’ corporate parent, PQ Corporation and was a critical member of a cross-functional team that divested two reportable segments (including Potters), with total enterprise value of over $1.7B. Andrew began his career at KPMG as a member of its tax practice. He holds a B.S. in Accounting from Drexel University, summa cum laude.

Dr. Morin is an expert in scientific communications who is passionate about translating complex science into digestible information. He comes from an academic background where he spent several years working on drug discovery projects for traumatic brain injuries. Later, he worked in a CRO helping design studies for different indications. Most recently, Dr. Morin worked at Public Relations agency with multiple biotech clients increasing their visibility and reputation in front of stakeholders. At Annovis, Dr. Morin is driving communications efforts on all fronts ensuring the transparency and quality of the company's messaging.